How to appeal your TRICARE experimental or investigational denial
Carriers commonly deny coverage by labeling a treatment 'experimental' or 'investigational', a designation that bypasses the usual medical-necessity analysis. This guide is specific to TRICARE appeals.
Why TRICARE denies experimental or investigational
TRICARE is the U.S. Department of Defense health program covering active-duty servicemembers, retirees, and eligible family members. Appeals are governed by 32 CFR Part 199, administered by regional contractors (Humana Military and TriWest), with final review by the Defense Health Agency (DHA).
For experimental or investigational specifically: Carriers commonly deny coverage by labeling a treatment 'experimental' or 'investigational', a designation that bypasses the usual medical-necessity analysis. These denials are appealable, and many reverse when peer-reviewed evidence, compendia listings, or clinical-trial data are presented.
FDA approval for the indication, recognized compendia (NCCN, AHFS-DI, DrugDex), and CMS National Coverage Determinations defeat an 'experimental or investigational' label.
What TRICARE denies for experimental or investigational
The experimental or investigational services most often denied:
- Off-label oncology regimens
- Newer CAR-T and cellular therapies
- Proton beam therapy
- Genetic and biomarker testing (next-generation sequencing)
- Surgical techniques deemed novel
- Compassionate-use and expanded-access drugs
Why experimental or investigational claims get denied
A typical TRICARE experimental or investigational denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:
- Treatment is not specifically FDA-approved for the indication
- Plan policy bulletin lists the service as investigational
- No randomized controlled trial cited in plan's policy
- Service is not in a recognized compendium for the diagnosis
The TRICARE appeal process
Appeal levels: Contractor reconsideration, formal review by DHA, then independent hearing (above the amount-in-controversy threshold), then DHA Director final decision.
Carrier timing: 90 days from denial for reconsideration; 60 days from each subsequent adverse decision for the next level. Urgent / pre-authorization timelines compress to 72 hours.
Experimental timing: Internal appeal: 180 days from denial. External review: typically 4 months / 120 days from final internal denial. Expedited urgent review: 72 hours.
What we know about TRICARE: TRICARE rules are federal, state DOI external review does not apply. We brief appeals against 32 CFR Part 199 and the TRICARE Operations Manual specifically.
Common TRICARE denial patterns for experimental or investigational
- Regional contractor reconsideration first. TRICARE appeals begin with reconsideration by the regional managed care support contractor, Humana Military (East) or TriWest (West). The reconsideration request must be in writing and is typically due within 90 days of the initial denial.
- Formal review by DHA. After contractor reconsideration, members can request a formal review by the Defense Health Agency. This step is the gateway to a hearing and is the prerequisite to any further federal review.
- Independent hearing for higher-dollar cases. TRICARE provides an independent hearing for appeals meeting a minimum amount-in-controversy threshold. The hearing officer's recommendation goes to the DHA Director for a final agency decision.
How to win your TRICARE experimental or investigational appeal
Strategy for experimental or investigational: Identify the plan's exact 'experimental/investigational' policy bulletin and rebut it point-by-point. Cite NCCN, ASCO, AHFS-DI, DrugDex, or other recognized compendia for the indication. Attach peer-reviewed literature and any clinical-trial enrollment data. Many state external review programs apply a heightened standard for E/I denials, once the case reaches external review, the IRO physician panel often overturns.
Filed against TRICARE, that strategy rides on this procedural spine:
- Procedural-rights anchor. Every TRICARE denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
- Criteria-disclosure demand. TRICARE frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
- Controlling-standard citation. FDA approval for the indication, recognized compendia (NCCN, AHFS-DI, DrugDex), and CMS National Coverage Determinations defeat an 'experimental or investigational' label.
- Treating-provider attestation. A letter from the treating physician addressing each criterion in TRICARE's own policy language. This is the single strongest evidentiary element.
- Requested action. A specific demand to reverse the experimental or investigational denial and approve the service, not a general "please reconsider."
Documents you'll need for your TRICARE experimental or investigational appeal
- Denial letter (with plan's E/I policy bulletin)
- Treating physician's letter of medical necessity
- Peer-reviewed literature supporting the therapy
- Compendium entry (NCCN, ASCO, AHFS-DI, DrugDex)
- Pathology / diagnostic report
What a experimental or investigational appeal can recover
Typical recovery for experimental or investigational cases runs $5,000 - $500,000+ depending on therapy. The exact figure depends on the specific service and your plan's contracted rates.
TRICARE experimental or investigational appeals: frequently asked questions
Can I appeal an 'experimental or investigational' denial from TRICARE?
Yes, and these reverse often at external review. Identify the plan's exact experimental/investigational policy bulletin and rebut it point by point with FDA approval for the indication, recognized compendia, and peer-reviewed evidence.
What beats an 'experimental' label?
FDA approval for the specific indication, a recognized compendium entry (NCCN, AHFS-DI, DrugDex), a CMS national coverage determination, and peer-reviewed literature. Many state external-review programs apply a heightened standard for these denials.
How long do I have for an experimental-denial appeal?
Internal appeals are due within 180 days. External review is typically available within 4 months (120 days) of the final internal denial, and urgent cases qualify for 72-hour expedited review.
Why does TRICARE call a standard treatment experimental?
Usually because the therapy is not specifically FDA-approved for that indication, the plan's bulletin lists it as investigational, or no randomized trial is cited in the policy. A compendium entry for your diagnosis directly contradicts that classification.
What Apellica does for TRICARE experimental or investigational appeals
We file appeals against TRICARE specifically configured to its internal review process. Every experimental or investigational appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.
Cost: $0 upfront. We work on contingency for TRICARE appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.
Start your TRICARE experimental or investigational appeal
Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.
Start free appeal review →Related TRICARE guides
- TRICARE surgery denials appeal guide
- TRICARE mri and imaging denials appeal guide
- TRICARE medication and prescription denials appeal guide
- TRICARE medicare denials appeal guide